Phreesia, Inc. (PHR)
Largest Insider Buys in Sector
PHR Stock Price History Chart
PHR Stock Performance
About Phreesia, Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and …
Insider Activity of Phreesia, Inc.
Over the last 12 months, insiders at Phreesia, Inc. have bought $0 and sold $11.32M worth of Phreesia, Inc. stock.
On average, over the past 5 years, insiders at Phreesia, Inc. have bought $0 and sold $31.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Phreesia, Inc.
| 2024-12-18 | Sale | General Counsel & Secretary | 3,495 0.0064% | $24.88 | $86,956 | +0.76% | ||
| 2024-12-18 | Sale | SVP, Life Sciences | 24 <0.0001% | $25.38 | $609 | -1.21% | ||
| 2024-12-17 | Sale | SVP, Life Sciences | 61 0.0001% | $25.06 | $1,529 | +1.21% | ||
| 2024-12-16 | Sale | director | 861 0.0015% | $25.26 | $21,752 | -2.46% | ||
| 2024-12-16 | Sale | SVP, Life Sciences | 35 <0.0001% | $24.88 | $871 | -2.46% | ||
| 2024-12-13 | Sale | director | 20,565 0.0354% | $25.04 | $515,038 | +0.88% | ||
| 2024-12-11 | Sale | director | 18,574 0.0325% | $25.10 | $466,191 | +0.65% | ||
| 2024-12-11 | Sale | SVP, Life Sciences | 11,853 0.0205% | $24.85 | $294,559 | +0.65% | ||
| 2024-12-10 | Sale | Chief Operating Officer | 25,000 0.0433% | $24.09 | $602,160 | +3.15% | ||
| 2024-12-03 | Sale | SVP, Human Resources | 25,447 0.0446% | $20.93 | $532,560 | +17.46% | ||
| 2024-12-02 | Sale | director | 15,152 0.0259% | $21.01 | $318,368 | +15.38% | ||
| 2024-10-18 | Sale | SVP, Life Sciences | 1,100 0.002% | $20.49 | $22,539 | +6.57% | ||
| 2024-10-16 | Sale | Principal Accounting Officer | 423 0.0007% | $21.33 | $9,023 | +0.86% | ||
| 2024-10-15 | Sale | Chief Executive Officer | 3,089 0.0051% | $21.03 | $64,947 | -0.19% | ||
| 2024-10-15 | Sale | Chief Operating Officer | 1,843 0.003% | $21.03 | $38,749 | -0.19% | ||
| 2024-10-15 | Sale | SVP, Life Sciences | 2,011 0.0033% | $21.03 | $42,281 | -0.19% | ||
| 2024-10-15 | Sale | General Counsel & Secretary | 1,212 0.002% | $21.03 | $25,482 | -0.19% | ||
| 2024-10-15 | Sale | SVP, Human Resources | 624 0.001% | $21.03 | $13,120 | -0.19% | ||
| 2024-10-15 | Sale | Chief Financial Officer | 864 0.0014% | $21.03 | $18,166 | -0.19% | ||
| 2024-10-15 | Sale | Principal Accounting Officer | 2,791 0.0046% | $20.92 | $58,395 | -0.19% |
Institutional Investor Ownership
| Fidelity Investments | $183.93M | 13.39 | 7.69M | -0.08% | -$144,082.53 | 0.01 | |
| The Vanguard Group | $109.31M | 7.96 | 4.57M | -1.31% | -$1.45M | <0.01 | |
| Brown Advisory | $100.88M | 7.35 | 4.22M | +6.72% | +$6.35M | 0.14 | |
| BlackRock | $99.47M | 7.24 | 4.16M | -2.23% | -$2.27M | <0.01 | |
| Capital International Investors | $62.05M | 4.52 | 2.59M | +221.08% | +$42.73M | 0.01 |